DOCSLIB.ORG

TMIC List of Metabolites.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TMIC List of Metabolites.Indd List of metabolites identified and quantified by TMIC analytical services Direct Flow Injection Mass Spectrometry (DI-MS) HMDB00641 Glutamine Amino Acids HMDB # Metabolites Classification HMDB00123 Glycine Amino Acids HMDB03357 Acetylornithine Biogenic amines HMDB00177 Histidine Amino Acids HMDB01539 Asymmetric dimethylarginine Biogenic amines HMDB00172 Isoleucine Amino Acids HMDB03334 Symmetric dimethylarginine Biogenic amines HMDB00687 Leucine Amino Acids total dimethylarginine Biogenic amines HMDB00182 Lysine Amino Acids alpha-Aminoadipicacid Biogenic amines HMDB00696 Methionine Amino Acids HMDB00033 Carnosine Biogenic amines HMDB00214 Ornithine Amino Acids HMDB00562 Creatinine Biogenic amines HMDB00159 Phenylalanine Amino Acids HMDB00181 Dopa Biogenic amines HMDB00162 Proline Amino Acids HMDB00073 Dopamine Biogenic amines HMDB00187 Serine Amino Acids HMDB00870 Histamine Biogenic amines HMDB00167 Threonine Amino Acids HMDB00684 Kynurenine Biogenic amines HMDB00929 Tryptophan Amino Acids Methioninesulfoxide Biogenic amines HMDB00158 Tyrosine Amino Acids Nitrotyrosine Biogenic amines HMDB00883 Valine Amino Acids Hydroxyproline Biogenic amines C0 (Carnitine) Acylcarnitines HMDB12275 Phenylethylamine Biogenic amines C10 (Decanoylcarnitine) Acylcarnitines HMDB01414 Putrescine Biogenic amines C10:1 (Decenoylcarnitine) Acylcarnitines HMDB00271 Sarcosine Biogenic amines C10:2 (decadienylcarnitine) Acylcarnitines HMDB00259 Serotonin Biogenic amines C12 (dodecanoylcarnitine) Acylcarnitines HMDB01257 Spermidine Biogenic amines C12:1 (Dodecenoylcarnitine) Acylcarnitines HMDB01256 Spermine Biogenic amines C12-DC (dodecanedioylcarnitine) Acylcarnitines HMDB00251 Taurine Biogenic amines C14 (tetradecanoylcarnitine) Acylcarnitines HMDB00161 Alanine Amino Acids C14:1 (tetradecenoyl carnitine) Acylcarnitines HMDB00517 Arginine Amino Acids C14:1-OH (Hydroxytetradecenoyl carnitine) Acylcarnitines HMDB00168 Asparagine Amino Acids C14:2 (Tetradecadienylcarnitine) Acylcarnitines HMDB00191 Aspartate Amino Acids C14:2-OH (hydroxytetradecadienylcarnitine) Acylcarnitines HMDB00904 Citrulline Amino Acids C16 (Hexadecanoylcarnitine) Acylcarnitines HMDB03339 Glutamate Amino Acids C16:1 (Hexadecenoylcarnitine) Acylcarnitines TMIC is Canada‘ s national metabolomics facility supporting a wide range of state-of-the-art metabolomics analysis for clinical trials research, biomedical studies, bio-products studies, nutrient profiling, and environmental testing. 1 C16:1-OH (Hydroxyhexadecenoylcarnitine) Acylcarnitines PC aa C32:0 Phospholipids C16:2 (Hexadecadienylcarnitine) Acylcarnitines PC aa C32:1 Phospholipids C16:2-OH (hydroxyhexadecadienylcarnitine) Acylcarnitines PC aa C32:2 Phospholipids C16-OH (hydroxyhexadecanoylcarnitine) Acylcarnitines PC aa C32:3 Phospholipids C18 (Octadecanoylcarnitine) Acylcarnitines PC aa C34:1 Phospholipids C18:1 (Octadecenoylcarnitine) Acylcarnitines PC aa C34:2 Phospholipids C18:1-OH (Hydroxyoctadecenoylcarnitine) Acylcarnitines PC aa C34:3 Phospholipids C18:2 (Octadecadienylcarnitine) Acylcarnitines PC aa C34:4 Phospholipids C2 (Acetylcarnitine) Acylcarnitines PC aa C36:0 Phospholipids C3 (Propionylcarnitine) Acylcarnitines PC aa C36:1 Phospholipids C3:1 (Propenoylcarnitine) Acylcarnitines PC aa C36:2 Phospholipids C3-OH (hydroxyPropionylcarnitine) Acylcarnitines PC aa C36:3 Phospholipids C4 (butyrylcarnitine) Acylcarnitines PC aa C36:4 Phospholipids C4-OH (C3-DC) (Hydroxybutyrylcarnitine) Acylcarnitines PC aa C36:5 Phospholipids C4:1 (Butenylcarnitine) Acylcarnitines PC aa C36:6 Phospholipids C5 (Valerylcarnitine) Acylcarnitines PC aa C38:0 Phospholipids C5-DC (C6-OH)(Glutarylcarnitine) Acylcarnitines PC aa C38:1 Phospholipids C5-M-DC (methylglutarylcarnitine) Acylcarnitines PC aa C38:3 Phospholipids C5-OH (C3-DC-M) (hydroxyvalerylcarnitine) Acylcarnitines PC aa C38:4 Phospholipids C5:1 (Tiglylcarnitine) Acylcarnitines PC aa C38:5 Phospholipids C5:1-DC (Glutaconylcarnitine) Acylcarnitines PC aa C38:6 Phospholipids C6 (C4:1-DC) (Hexanoylcarnitine) Acylcarnitines PC aa C40:1 Phospholipids C6:1 (Hexenoylcarnitine) Acylcarnitines PC aa C40:2 Phospholipids C7-DC (pimelylcarnitine) Acylcarnitines PC aa C40:3 Phospholipids C8 (Octanoylcarnitine) Acylcarnitines PC aa C40:4 Phospholipids C9 (Nonaylcarnitine) Acylcarnitines PC aa C40:5 Phospholipids HMDB00143 Hexose Carbohydrates PC aa C40:6 Phospholipids lysoPC a C14:0 Phospholipids PC aa C42:0 Phospholipids lysoPC a C16:0 Phospholipids PC aa C42:1 Phospholipids lysoPC a C16:1 Phospholipids PC aa C42:2 Phospholipids lysoPC a C17:0 Phospholipids PC aa C42:4 Phospholipids lysoPC a C18:0 Phospholipids PC aa C42:5 Phospholipids lysoPC a C18:1 Phospholipids PC aa C42:6 Phospholipids lysoPC a C18:2 Phospholipids PC ae C30:0 Phospholipids lysoPC a C20:3 Phospholipids PC ae C30:1 Phospholipids lysoPC a C20:4 Phospholipids PC ae C32:1 Phospholipids lysoPC a C24:0 Phospholipids PC ae C32:2 Phospholipids lysoPC a C26:0 Phospholipids lysoPC a C26:1 Phospholipids PC ae C34:0 Phospholipids lysoPC a C28:0 Phospholipids PC ae C34:1 Phospholipids lysoPC a C28:1 Phospholipids PC ae C34:2 Phospholipids PC aa C24:0 Phospholipids PC ae C34:3 Phospholipids PC aa C26:0 Phospholipids PC ae C36:0 Phospholipids PC aa C28:1 Phospholipids PC ae C36:1 Phospholipids PC aa C30:0 Phospholipids PC ae C36:2 Phospholipids PC aa C30:2 Phospholipids PC ae C36:3 Phospholipids 2 PC ae C36:4 Phospholipids HMDB01857 1,3-Dimethyluric acid PC ae C36:5 Phospholipids HMDB03331 1-Methyladenosine PC ae C38:0 Phospholipids HMDB00001 1-Methylhistidine PC ae C38:1 Phospholipids HMDB00699 1-Methylnicotinamide PC ae C38:2 Phospholipids HMDB00439 2-Furoylglycine PC ae C38:3 Phospholipids HMDB00317 2-Hydroxy-3-methylpentanoic acid PC ae C38:4 Phospholipids HMDB00008 2-Hydroxybutyric acid PC ae C38:5 Phospholipids HMDB00694 2-Hydroxyglutaric acid PC ae C38:6 Phospholipids HMDB00005 2-Ketobutyric acid PC ae C40:1 Phospholipids HMDB00354 2-Methyl-3-hydroxybutyric acid PC ae C40:2 Phospholipids HMDB00408 2-Methyl-3-ketovaleric acid PC ae C40:3 Phospholipids HMDB00339 2-Methylbutyrylglycine PC ae C40:4 Phospholipids HMDB11659 2-Methylerythritol PC ae C40:5 Phospholipids HMDB00422 2-Methylglutaric acid PC ae C40:6 Phospholipids HMDB03911 3-Aminoisobutanoic acid PC ae C42:0 Phospholipids HMDB00357 3-Hydroxybutyric acid PC ae C42:1 Phospholipids HMDB06116 3-Hydroxyhippuric acid HMDB00754 3-Hydroxyisovaleric acid PC ae C42:2 Phospholipids HMDB00355 3-Hydroxymethylglutaric acid PC ae C42:3 Phospholipids HMDB00440 3-Hydroxyphenylacetic acid PC ae C42:4 Phospholipids HMDB00491 3-Methyl-2-oxovaleric acid PC ae C42:5 Phospholipids HMDB00555 3-Methyladipic acid PC ae C44:3 Phospholipids HMDB00522 3-Methylglutaconic acid PC ae C44:4 Phospholipids HMDB00479 3-Methylhistidine PC ae C44:5 Phospholipids HMDB01886 3-Methylxanthine HMDB00112 4-Aminobutyric acid PC ae C44:6 Phospholipids HMDB01867 4-Aminohippuric acid SM (OH) C14:1 Sphingolipids HMDB02453 4-Deoxythreonic acid SM (OH) C16:1 Sphingolipids HMDB29306 4-Ethylphenol SM (OH) C22:1 Sphingolipids HMDB00500 4-Hydroxybenzoic acid SM (OH) C22:2 Sphingolipids HMDB00710 4-Hydroxybutyric acid SM (OH) C24:1 Sphingolipids HMDB13678 4-Hydroxyhippuric acid SM C16:0 Sphingolipids MSEA0510 4-Hydroxyphenyllactic acid SM C16:1 Sphingolipids HMDB00017 4-Pyridoxic acid HMDB00076 5,6-Dihydrouracil SM C18:0 Sphingolipids HMDB01149 5-Aminolevulinic acid SM C18:1 Sphingolipids HMDB03355 5-Aminopentanoic acid SM C20:2 Sphingolipids HMDB01991 7-Methylxanthine SM C22:3 Sphingolipids HMDB00990 Acetaldehyde SM C24:0 Sphingolipids HMDB01859 Acetaminophen SM C24:1 Sphingolipids HMDB10316 Acetaminophen glucuronide SM C26:0 Sphingolipids HMDB59911 Acetaminophen sulfate HMDB00042 Acetic acid SM C26:1 Sphingolipids HMDB00060 Acetoacetic acid Quantitative NMR Spectroscopy HMDB01659 Acetone HMDB Metabolites HMDB00201 Acetyl-L-carnitine HMDB00002 1,3-Diaminopropane HMDB00034 Adenine 3 HMDB00050 Adenosine HMDB00661 Glutaric acid HMDB00448 Adipic acid HMDB00139 Glyceric acid HMDB01341 ADP HMDB00131 Glycerol HMDB00462 Allantoin HMDB00123 Glycine HMDB00510 Alpha-Aminoadipic acid HMDB00115 Glycolic acid HMDB00452 Alpha-Aminobutyric acid HMDB00128 Guanidoacetic acid HMDB00729 Alpha-Hydroxyisobutyric acid HMDB00714 Hippuric acid HMDB00019 Alpha-Ketoisovaleric acid HMDB00679 Homocitrulline HMDB00194 Anserine HMDB00130 Homogentisic acid HMDB01851 Arabinitol HMDB00118 Homovanillic acid HMDB00044 Ascorbic acid HMDB02643 HPHPA HMDB01539 Asymmetric dimethylarginine HMDB00725 Hydroxyproline HMDB00784 Azelaic acid HMDB00700 Hydroxypropionic acid HMDB01870 Benzoic acid HMDB00157 Hypoxanthine HMDB00056 Beta-Alanine HMDB00197 Indoleacetic acid HMDB00043 Betaine HMDB00682 Indoxyl sulfate HMDB00039 Butyric acid HMDB00195 Inosine HMDB01847 Caffeine HMDB01873 Isobutyric acid HMDB00033 Carnosine HMDB00193 Isocitric acid HMDB00097 Choline HMDB00718 Isovaleric acid HMDB00567 Cinnamic acid HMDB00678 Isovalerylglycine HMDB00072 Cis-Aconitic acid HMDB00715 Kynurenic acid HMDB00634 Citraconic acid HMDB00684 Kynurenine HMDB00426 Citramalic acid HMDB00186 Lactose HMDB00094 Citric acid HMDB00161 L-Alanine HMDB00064 Creatine HMDB00646 L-Arabinose HMDB00562 Creatinine HMDB00517 L-Arginine HMDB00630 Cytosine HMDB00168 L-Asparagine HMDB01264 Dehydroascorbic acid HMDB00191 L-Aspartic acid HMDB00143 D-Galactose HMDB00062 L-Carnitine HMDB00122 D-Glucose HMDB00099 L-Cystathionine HMDB00079 Dihydrothymine HMDB00574 L-Cysteine HMDB04983 Dimethyl sulfone HMDB00192 L-Cystine HMDB00087 Dimethylamine HMDB00640 Levoglucosan HMDB00092 Dimethylglycine HMDB00720 Levulinic
Load more

Recommended publications
  • Hyperbranched Polyaspartate Esters and a Process for Their Preparation
    Europäisches Patentamt *EP000743335B1* (19) European Patent Office Office européen des brevets (11) EP 0 743 335 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C08G 63/685 of the grant of the patent: 26.09.2001 Bulletin 2001/39 (21) Application number: 96107069.5 (22) Date of filing: 06.05.1996 (54) Hyperbranched polyaspartate esters and a process for their preparation Hyperverzweigte Polyaspartatester und Verfahren zu ihrer Herstellung Ester de polyaspartate hyperramifiés et procédé pour leur préparation (84) Designated Contracting States: (74) Representative: Pettrich, Klaus-Günter, Dr. AT BE CH DE ES FR GB IT LI NL SE c/o Bayer AG, Konzernbereich RP (30) Priority: 18.05.1995 US 443505 Patente und Lizenzen 51368 Leverkusen (DE) (43) Date of publication of application: 20.11.1996 Bulletin 1996/47 (56) References cited: US-A- 5 126 170 (73) Proprietor: Bayer Corporation Pittsburgh, PA 15205-9741 (US) • ISRA L JOURNAL OF CHEMISTRY, vol. 9, 1971, JERUSALEM, pages 105-109, XP000670606 A. (72) Inventors: SINGERMAN ET AL.: "Poly threo-beta-hydroxy • Yeske, Philip E. aspartic acid" Pittsburgh, PA 15228 (US) • Gindin, Lyuba K. Remarks: Pittsburgh, PA 15216 (US) The file contains technical information submitted • Wicks, Douglas A. after the application was filed and not included in this Mt. Lebanon, PA 15228 (US) specification • Jonsson, E. Haakan Coraopolis, PA 15108 (US) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement.
    [Show full text]
  • Antioxidants and Second Messengers of Free Radicals
    antioxidants Antioxidants and Second Messengers of Free Radicals Edited by Neven Zarkovic Printed Edition of the Special Issue Published in Antioxidants www.mdpi.com/journal/antioxidants Antioxidants and Second Messengers of Free Radicals Antioxidants and Second Messengers of Free Radicals Special Issue Editor Neven Zarkovic MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade Special Issue Editor Neven Zarkovic Rudjer Boskovic Institute Croatia Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Antioxidants (ISSN 2076-3921) from 2018 (available at: https://www.mdpi.com/journal/ antioxidants/special issues/second messengers free radicals) For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03897-533-5 (Pbk) ISBN 978-3-03897-534-2 (PDF) c 2019 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Special Issue Editor ...................................... vii Preface to ”Antioxidants and Second Messengers of Free Radicals” ................ ix Neven Zarkovic Antioxidants and Second Messengers of Free Radicals Reprinted from: Antioxidants 2018, 7, 158, doi:10.3390/antiox7110158 ...............
    [Show full text]
  • Cloning, Biochemical Characterization and Inhibition of Alanine Racemase from Streptococcus Iniae
    bioRxiv preprint doi: https://doi.org/10.1101/611251; this version posted April 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cloning, Biochemical Characterization and Inhibition of Alanine racemase from Streptococcus iniae Murtala Muhammad, Yangyang Li, Siyu Gong, Yanmin Shi, Jiansong Ju, Baohua Zhao*, Dong Liu* College of Life Science, Hebei Normal University, Shijiazhuang 050024, China; *Correspondence: Baohua Zhao and Dong Liu; E-mail: [email protected], [email protected]; College of Life Science, Hebei Normal University, Shijiazhuang 050024, China. Running Title: Inhibitors of alanine racemase Summary statement: Antimicrobial target 1 bioRxiv preprint doi: https://doi.org/10.1101/611251; this version posted April 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Streptococcus iniae is a pathogenic and zoonotic bacteria that impacted high mortality to many fish species, as well as capable of causing serious disease to humans. Alanine racemase (Alr, EC 5.1.1.1) is a pyridoxal-5′-phosphate (PLP)-containing homodimeric enzyme that catalyzes the racemization of L-alanine and D-alanine. In this study, we purified alanine racemase from the pathogenic strain of S. iniae, determined its biochemical characteristics and inhibitors. The alr gene has an open reading frame (ORF) of 1107 bp, encoding a protein of 369 amino acids, which has a molecular mass of 40 kDa. The optimal enzyme activity occurred at 35°C and a pH of 9.5.
    [Show full text]
  • US EPA Inert (Other) Pesticide Ingredients
    U.S. Environmental Protection Agency Office of Pesticide Programs List of Inert Pesticide Ingredients List 3 - Inerts of unknown toxicity - By Chemical Name UpdatedAugust 2004 Inert Ingredients Ordered Alphabetically by Chemical Name - List 3 Updated August 2004 CAS PREFIX NAME List No. 6798-76-1 Abietic acid, zinc salt 3 14351-66-7 Abietic acids, sodium salts 3 123-86-4 Acetic acid, butyl ester 3 108419-35-8 Acetic acid, C11-14 branched, alkyl ester 3 90438-79-2 Acetic acid, C6-8-branched alkyl esters 3 108419-32-5 Acetic acid, C7-9 branched, alkyl ester C8-rich 3 2016-56-0 Acetic acid, dodecylamine salt 3 110-19-0 Acetic acid, isobutyl ester 3 141-97-9 Acetoacetic acid, ethyl ester 3 93-08-3 2'- Acetonaphthone 3 67-64-1 Acetone 3 828-00-2 6- Acetoxy-2,4-dimethyl-m-dioxane 3 32388-55-9 Acetyl cedrene 3 1506-02-1 6- Acetyl-1,1,2,4,4,7-hexamethyl tetralin 3 21145-77-7 Acetyl-1,1,3,4,4,6-hexamethyltetralin 3 61788-48-5 Acetylated lanolin 3 74-86-2 Acetylene 3 141754-64-5 Acrylic acid, isopropanol telomer, ammonium salt 3 25136-75-8 Acrylic acid, polymer with acrylamide and diallyldimethylam 3 25084-90-6 Acrylic acid, t-butyl ester, polymer with ethylene 3 25036-25-3 Acrylonitrile-methyl methacrylate-vinylidene chloride copoly 3 1406-16-2 Activated ergosterol 3 124-04-9 Adipic acid 3 9010-89-3 Adipic acid, polymer with diethylene glycol 3 9002-18-0 Agar 3 61791-56-8 beta- Alanine, N-(2-carboxyethyl)-, N-tallow alkyl derivs., disodium3 14960-06-6 beta- Alanine, N-(2-carboxyethyl)-N-dodecyl-, monosodium salt 3 Alanine, N-coco alkyl derivs.
    [Show full text]
  • Detection and Formation Scenario of Citric Acid, Pyruvic Acid, and Other Possible Metabolism Precursors in Carbonaceous Meteorites
    Detection and formation scenario of citric acid, pyruvic acid, and other possible metabolism precursors in carbonaceous meteorites George Coopera,1, Chris Reeda, Dang Nguyena, Malika Cartera, and Yi Wangb aExobiology Branch, Space Science Division, National Aeronautics and Space Administration-Ames Research Center, Moffett Field, CA 94035; and bDevelopment, Planning, Research, and Analysis/ZymaX Forensics Isotope, 600 South Andreasen Drive, Suite B, Escondido, CA 92029 Edited by David Deamer, University of California, Santa Cruz, CA, and accepted by the Editorial Board July 1, 2011 (received for review April 12, 2011) Carbonaceous meteorites deliver a variety of organic compounds chained three-carbon (3C) pyruvic acid through the eight-carbon to Earth that may have played a role in the origin and/or evolution (8C) 7-oxooctanoic acid and the branched 6C acid, 3-methyl- of biochemical pathways. Some apparently ancient and critical 4-oxopentanoic acid (β-methyl levulinic acid), Fig. 1, Table S1. metabolic processes require several compounds, some of which 2-methyl-4-oxopenanoic acid (α-methyl levulinic acid) is tenta- are relatively labile such as keto acids. Therefore, a prebiotic setting tively identified (i.e., identified by mass spectral interpretation for any such individual process would have required either a only). As a group, these keto acids are relatively unusual in that continuous distant source for the entire suite of intact precursor the ketone carbon is located in a terminal-acetyl group rather molecules and/or an energetic and compact local synthesis, parti- than at the second carbon as in most of the more biologically cularly of the more fragile members.
    [Show full text]
  • The Clinical Significance of the Organic Acids Test
    The Clinical Significance of the Organic Acids Test The Organic Acids Test (OAT) provides an accurate metabolic snapshot of what is going on in the body. Besides offering the most complete and accurate evaluation of intestinal yeast and bacteria, it also provides information on important neurotransmitters, nutritional markers, glutathione status, oxalate metabolism, and much more. The test includes 76 urinary metabolite markers that can be very useful for discovering underlying causes of chronic illness. Patients and physicians report that treating yeast and bacterial abnormalities reduces fatigue, increases alertness and energy, improves sleep, normalizes bowel function, and reduces hyperactivity and abdominal pain. The OAT Assists in Evaluating: ■ Krebs Cycle Abnormalities ■ Neurotransmitter Levels ■ Nutritional Deficiencies ■ Antioxidant Deficiencies ■ Yeast and Clostridia Overgrowth ■ Fatty Acid Metabolism ■ Oxalate Levels ■ And More! The OAT Pairs Well with the Following Tests: ■ GPL-TOX: Toxic Non-Metal Chemical Profile ■ IgG Food Allergy + Candida ■ MycoTOX Profile ■ Phospholipase A2 Activity Test Learn how to better integrate the OAT into your practice, along with our other top tests by attending one of our GPL Academy Practitioner Workshops! Visit www.GPLWorkshops.com for workshop dates and locations. The following pages list the 76 metabolite markers of the Organic Acids Test. Included is the name of the metabolic marker, its clinical significance, and usual initial treatment. INTESTINAL MICROBIAL OVERGROWTH Yeast and Fungal Markers Elevated citramalic acid is produced mainly by Saccharomyces species or Propionibacteria Citramalic Acid overgrowth. High-potency, multi-strain probiotics may help rebalance GI flora. A metabolite produced by Aspergillus and possibly other fungal species in the GI tract. 5-Hydroxy-methyl- Prescription or natural antifungals, along with high-potency, multi-strain probiotics, furoic Acid may reduce overgrowth levels.
    [Show full text]
  • Profiling Taste and Aroma Compound Metabolism During Apricot Fruit Development and Ripening
    Int. J. Mol. Sci. 2016, 17, 998; doi:10.3390/ijms17070998 S1 of S4 Supplementary Materials: Profiling Taste and Aroma Compound Metabolism during Apricot Fruit Development and Ripening Wanpeng Xi, Huiwen Zheng, Qiuyun Zhang and Wenhui Li Figure S1. Sugars HPLC chromatogram of apricot fruit. Peaks (1) Fructose (2) Glucose (3) Sucrose. (a) sugars mixture standards; (b) sugars for SG peel of S5; (c) sugars for SG pulp of S5. Int. J. Mol. Sci. 2016, 17, 998; doi:10.3390/ijms17070998 S2 of S4 Figure S2. Organic acids HPLC chromatogram of apricot fruit. Peaks (1) oxalic acid (2) tartaric acid (3) quininic acid (4) malic acid (5) citric acid (6) fumaric acid. (a) organic acids mixture standard; (b) organic acid for YC peel of S4; (c) organic acid for YC pulp of S4. Int. J. Mol. Sci. 2016, 17, 998; doi:10.3390/ijms17070998 S3 of S4 Table S1. Chroma values of apricot fruit during development and ripening. L* a* b* C* H Cultivars S1 S2 S3 S4 S5 S1 S2 S3 S4 S5 S1 S2 S3 S4 S5 S1 S2 S3 S4 S5 S1 S2 S3 S4 S5 DX 54.52 57.13 61.56 62.61 55.49 20.28 18.13 14.41 8.87 17.97 39.02 37.67 38.27 39.99 43.83 43.98 42.27 41.06 42.26 47.67 117.46 116.92 110.21 76.26 67.36 HY 54.97 55.83 61.53 65.08 65.11 −16.04 −14.77 −13.30 11.01 12.78 34.44 31.68 32.74 38.82 42.51 37.99 34.84 35.35 52.69 45.14 114.91 114.94 112.05 72.65 72.57 KE 47.02 47.00 48.32 60.11 60.66 −17.08 −17.37 −16.65 −0.36 8.20 30.83 29.09 29.08 48.23 48.48 35.26 33.88 33.51 48.33 49.33 118.94 120.86 119.85 90.67 118.02 AK 50.02 50.90 52.19 68.35 60.28 −21.98 −21.76 −19.02 -4.97 4.04 40.07 39.12 35.71
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Oxaloacetate As the Hill Oxidant in Mesophyll Cells of Plants Possessing
    Proc. Nat. Acad. Sci. USA Vol. 70, No. 12, Part II, pp. 3730-3734, December 1973 Oxaloacetate as the Hill Oxidant in Mesophyll Cells of Plants Possessing the C4-Dicarboxylic Acid Cycle of Leaf Photosynthesis (CO2 fixation/uncoupler/photochemical reactions/electron transport/02 evolution) MARVIN L. SALIN, WILBUR H. CAMPBELL, AND CLANTON C. BLACK, JR. Department of Biochemistry, University of Georgia, Athens, Ga. 30602 Communicated by Harland G. Wood, August 16, 1973 ABSTRACT Isolated mesophyll cells from leaves of NADP+-dependent malic dehydrogenase (10) is in the meso- plants that use the C4 dicarboxylic acid pathway of CO2 fixation have been used to demonstrate that oxaloacetic phyll cells (9, 11). Therefore, one could reason that in meso- acid reduction to malic acid is coupled to the photo- phyll cells the carboxylation of PEP should be coupled to the chemical evolution of oxygen through the presumed pro- reduction of OAA and the required reduced pyridine nucleo- duction ofNADPH. The major acid-stable product oflight- tide should be produced photosynthetically as follows: dependent CO2 fixation is shown to be malic acid. In the presence of phosphoenolpyruvate and bicarbonate the PEP stoichiometry of CO2 fixation into acid-stable products to HC03- + PEP OAA + Pi [1] 02 evolution is shown to be near 1.0. Thus oxaloacetic acid carboxylase acts directly as the Hill oxidant in mesophyll cell chloro- light plasts. The experiments are taken as a firm demonstration that the dicarboxylic acid cycle of photosynthesis is the NADP++H20 NADPH+ 1/202+H+ [2] C4 mesophyll cell major pathway for the fixation of CO2 in mesophyll cells chloroplasts of plants having this pathway.
    [Show full text]
  • The Human Urine Metabolome
    The Human Urine Metabolome Souhaila Bouatra1, Farid Aziat1, Rupasri Mandal1, An Chi Guo2, Michael R. Wilson2, Craig Knox2, Trent C. Bjorndahl1, Ramanarayan Krishnamurthy1, Fozia Saleem1, Philip Liu1, Zerihun T. Dame1, Jenna Poelzer1, Jessica Huynh1, Faizath S. Yallou1, Nick Psychogios3, Edison Dong1, Ralf Bogumil4, Cornelia Roehring4, David S. Wishart1,2,5* 1 Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada, 2 Department of Computing Sciences, University of Alberta, Edmonton, Alberta, Canada, 3 Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 4 BIOCRATES Life Sciences AG, Innsbruck, Austria, 5 National Institute for Nanotechnology, Edmonton, Alberta, Canada Abstract Urine has long been a ‘‘favored’’ biofluid among metabolomics researchers. It is sterile, easy-to-obtain in large volumes, largely free from interfering proteins or lipids and chemically complex. However, this chemical complexity has also made urine a particularly difficult substrate to fully understand. As a biological waste material, urine typically contains metabolic breakdown products from a wide range of foods, drinks, drugs, environmental contaminants, endogenous waste metabolites and bacterial by-products. Many of these compounds are poorly characterized and poorly understood. In an effort to improve our understanding of this biofluid we have undertaken a comprehensive, quantitative, metabolome-wide characterization of human urine. This involved both computer-aided literature mining and comprehensive, quantitative experimental assessment/validation. The experimental portion employed NMR spectroscopy, gas chromatography mass spectrometry (GC-MS), direct flow injection mass spectrometry (DFI/LC-MS/MS), inductively coupled plasma mass spectrometry (ICP-MS) and high performance liquid chromatography (HPLC) experiments performed on multiple human urine samples.
    [Show full text]
  • Transamination in Tumors, Fetal Tissues, and Regenerating Liver* Philip P
    Transamination in Tumors, Fetal Tissues, and Regenerating Liver* Philip P. Cohen, M.D., and G. Leverne Hekhuis (From the Laboratory o~ Physiological Chemistry, Yale University School of Medicine, New Haven, Connecticut) (Received for publication June 9, I94I) von Euler and co-workers (22), on the basis of TISSUE SOURCES results of essentially qualitative experiments, first re- Tumors.--The mouse tumors employed in this in- ported that the transaminase activity ot~ tumors was vestigation were the following: low. These investigators, using Jensen sarcoma and normal muscle, measured the rate of disappearance of I. United States Public Health Service No. ~7-- oxaloacetic acid in the following reaction: originally described as a neuroepithelioma (20). 1 2. Sarcoma 37 .1 3. Yale No. xuan estrogen-induced ,) 1( + )-glutamic acid + oxaloacetic acid a mammary adenocarcinoma (5). 1 4. No. x5o9I-A - ~'b a-ketoglutaric acid + aspartic acid spontaneous mammary medullary adenocarcinoma In addition to studies of reaction I in tumors, Braun- (6) "1 5- No. 42--glioblastoma multiforme. 2 6. No. stein and Azarkh (2) studied the reaction: i o8--rhabdomyosarcoma. 2 The tumors were transplanted at regular intervals 2) glutamic acid+a-keto acid to insure a uniform supply. a-ketoglutaric acid + amino acid "-b- Fetal, kitten, and adult cat tissues.--Two pregnant cats provided the fetal tissue. The length of the preg- The amino acids investigated in the case of reaction nancy was uncertain, but was estimated to be in the 2b were the d- and l-forms of alanine, valine, leucine, last trimester in both instances. Hemihysterectomies and isoleucine. The rate of reaction za in which both were performed under nembutal anesthesia and 2 d(--)- and l(+)-glutamic acid were used, plus fetuses removed from each animal.
    [Show full text]
  • Oxaloacetic Acid Supplementation As a Mimic of Calorie Restriction Alan Cash*
    22 Open Longevity Science, 2009, 3, 22-27 Open Access Oxaloacetic Acid Supplementation as a Mimic of Calorie Restriction Alan Cash* Terra Biological LLC, San Diego, CA 92130, USA Abstract: The reduction in dietary intake leads to changes in metabolism and gene expression that increase lifespan, re- duce the incidence of heart disease, kidney disease, Alzheimer’s disease, type-2 diabetes and cancer. While all the mo- lecular pathways which result in extended lifespan as a result of calorie restriction are not fully understood, some of these pathways that have resulted in lifespan expansion have been identified. Three molecular pathways activated by calorie re- striction are also shown to be activated by supplementing the diet with the metabolite oxaloacetic acid. Animal studies supplementing oxaloacetic acid show an increase in lifespan and other substantial health benefits including mitochondrial DNA protection, and protection of retinal, neural and pancreatic tissues. Human studies indicate a substantial reduction in fasting glucose levels and improvement in insulin resistance. Supplementation with oxaloacetic acid may be a safer method to mimic calorie restriction than the use of traditional diabetes drugs. INTRODUCTION citric acid cycle, and is found in every cell in the body. Fig. (1) shows a schematic diagram of the citric acid cycle and For over 75 years, scientists have known how to increase the position of oxaloacetate within the cycle. average and maximal lifespan; reduce dietary intake of calo- ries by 25 to 40% over ad libitum baseline values while maintaining adequate nutrition. This reduction in dietary intake leads to changes in metabolism and gene expression Oxaloacetate Citrate that increase lifespan, and also been reported to reduce the incidence of heart disease, kidney disease, Alzheimer’s dis- Malate ease, type-2 diabetes and cancer in animals [1-3].
    [Show full text]